Fig. 4 | Signal Transduction and Targeted Therapy

Fig. 4

From: p53: from understanding its structure to advances in therapeutic targeting

Fig. 4The alternative text for this image may have been generated using AI.

The activity status of the cGAS/STING pathway under the regulation of wild-type versus mutant TP53. a Normally, the activation of the cGAS/STING pathway induces type I interferons (IFNs) and initiates immune signaling pathways to suppress tumorigenesis. b Mutated p53 can disrupt the downstream cGAS/STING signaling pathway to promote tumorigenesis and immune evasion. This figure was created by BioRender.com

Back to article page